Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Wee1 inhibitors act on a nuclear tyrosine kinase that delays entry into mitosis after DNA damage. Wee1 phosphorylates cyclin-dependent kinase 1 (CDK1) on tyrosine 15 and so keeps the CDK1-cyclin B complex inactive, as shown for the human enzyme in 1992. Protein kinase membrane-associated tyrosine/threonine 1 (PKMYT1) phosphorylates CDK1 on both threonine 14 and tyrosine 15. Blocking these kinases pushes cells with damaged DNA into premature mitosis. This effect is studied together with DNA-damaging agents, often in tumor cells that lack a functional G1 checkpoint. Adavosertib is a selective Wee1 inhibitor, whereas PD0166285 and PD 407824 also block checkpoint kinases listed under Chk. XH-30 inhibits PKMYT1, and HEMTAC WEE1 degrader-1 removes Wee1 by targeted degradation.
WEE1/PKMYT1-IN-1 is a potent inhibitor targeting WEE1 and PKMYT1 kinases. This compound exhibits significant antiproliferative activity, making it suitable for research applications in cancer biology. It can be utilized to investigate cell cycle regulation and the mechanistic pathways involved in tumor cell proliferation.
PKMYT1-IN-1 is a selective inhibitor of the membrane-associated tyrosine and threonine kinase, PKMYT1, demonstrating an IC50 of 8.8 nM. This reagent effectively inhibits the proliferation of HCC1569 tumor cells with an IC50 of 42 nM, making it a valuable tool for research into cancer biology and therapeutic interventions targeting PKMYT1 pathways. Its specificity and potency offer significant potential for studying the role of PKMYT1 in oncogenic processes.
Myt1-IN-2 is a potent inhibitor of the membrane-associated cdc2-inhibitory kinase, Myt1 (Gene name: PKMYT1), demonstrating an IC50 of less than 10 nM. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Myt1-IN-2 can be utilized in studies aimed at elucidating the role of Myt1 in cell cycle regulation and its implications in oncogenesis.
PKMYT1-IN-9 is a selective inhibitor of PKMYT1, demonstrating an IC50 of 4.4 nM. This compound shows significantly higher selectivity for PKMYT1 compared to WEE1, which has an IC50 of 32.4 μM. PKMYT1-IN-9 has been characterized by its antitumor activity, making it a valuable tool in cancer research and therapeutic studies targeting checkpoint pathways.
Out of stock
All 3 sizes
WEE1-IN-12 is a potent Wee1 kinase inhibitor with an IC50 of 2.0 nM. It demonstrates significant antiproliferative effects in HT29 colorectal cancer cells, exhibiting an IC50 of 1.07 μM. The compound enhances the efficacy of Gemcitabine, showing improved activity with an IC50 of 0.34 μM in combination studies. WEE1-IN-12 is valuable for research into targeted therapies for tumors, particularly colon cancer.
Out of stock
All 3 sizes
PKMYT1-IN-2 is a potent inhibitor of PKMYT1, exhibiting an IC50 value of 5.7 nM. This compound effectively suppresses the growth of HCC1569 cancer cells with an IC50 of 22 nM. PKMYT1-IN-2 serves as a valuable tool for research in cancer biology, particularly in studies focused on targeting the PKMYT1 pathway for therapeutic interventions.
Out of stock
All 3 sizes
WEE1/PKMYT1-IN-2 is a potent inhibitor of WEE1 and PKMYT1 kinases, exhibiting an axial chiral P configuration. This compound demonstrates significant antiproliferative activity, making it a valuable tool for cancer research. It is particularly relevant for studies investigating cell cycle regulation and the therapeutic potential of targeting WEE1 and PKMYT1 in various malignancies.
Out of stock
All 3 sizes
i-AZD1775 TFA is an immobilizable analogue of AZD1775, functioning as a selective inhibitor of the WEE1 kinase. This compound exhibits significant potential in inhibiting cell cycle regulation, enabling the investigation of its efficacy in cancer cell lines. i-AZD1775 TFA is valuable for studies focused on anticancer therapies, particularly in exploring combination treatments and resistance mechanisms in various tumor types.
Out of stock
All 3 sizes
WEE1-IN-9 is a selective inhibitor of the Wee1 kinase, which plays a critical role in regulating the cell cycle by inhibiting the progression from G2 to mitosis. This compound exhibits potent anti-tumor activity and is valuable for studying the effects of Wee1 inhibition in cancer research. WEE1-IN-9 can be utilized in investigations of cancer cell proliferation and therapy resistance mechanisms, contributing to the development of novel cancer treatments.
Out of stock
All 3 sizes
WEE1-IN-6 is a potent WEE1 inhibitor with a DC50 value of ≤ 100 nM. This compound effectively inhibits cell proliferation, making it a valuable tool for studies related to cell cycle regulation and cancer research. Its oral bioactivity enables convenient administration in various in vivo studies targeting WEE1 pathways.
Out of stock
All 3 sizes
WEE1/PKMYT1-IN-3 is a potent inhibitor of WEE1 and PKMYT1, specifically designed with an axial chiral M configuration. This compound exhibits significant antiproliferative activity, making it a valuable tool for cancer research. It can be utilized to explore the mechanisms of cell cycle regulation and to investigate therapeutic strategies targeting these critical kinases in various malignancies.
Out of stock
All 3 sizes
WEE1-IN-8 is a highly selective WEE1 inhibitor, exhibiting an IC50 of 0.98 nM. This compound is effective in research applications targeting various malignancies, including pancreatic cancer, ovarian cancer, colorectal cancer, and uterine serous carcinoma. By facilitating the abrogation of G2/M checkpoint control, WEE1-IN-8 demonstrates potential as a therapeutic agent in cancer treatment strategies.
Out of stock
All 3 sizes
PKMYT1-IN-11 is a potent inhibitor of PKMYT1, exhibiting an IC50 of 4.49 nM. This compound effectively suppresses the proliferation of HCC1569 cancer cells and demonstrates a significant anti-tumor effect in combination with Gemcitabine in the OVCAR3 xenograft mouse model. PKMYT1-IN-11 is valuable for researching various cancers, including breast and ovarian cancer, providing insights into therapeutic strategies targeting PKMYT1.
Out of stock
All 3 sizes
WEE1-IN-11 is a potent inhibitor of the Wee1 kinase, demonstrating an impressive IC50 of 2.0 nM against CDK2. This compound effectively inhibits various cancer cell lines, including NCI-H446, A427, OVCAR3, C33A, and WiDr, with IC50 values of 93.9 nM, 34.5 nM, 86.7 nM, 23.1 nM, and 85 nM, respectively. It serves as a valuable tool for investigating cell cycle regulation and the therapeutic potential of targeting Wee1 in cancer research.
Out of stock
All 3 sizes
PKMYT1-IN-4 is a potent PKMYT1 inhibitor with an IC50 of less than 50 nM. This compound selectively targets the Wee1 kinase, a critical regulator of the cell cycle. PKMYT1-IN-4 is utilized in research applications focused on cell cycle regulation and cancer biology, making it suitable for studies exploring therapeutic strategies against proliferative diseases.
Out of stock
All 3 sizes
Myt1-IN-6 is a selective inhibitor of MYT1 kinase, which plays a crucial role in the regulation of cell cycle progression and neuronal differentiation. This compound is particularly relevant for studies involving RB1-deficient cancers, such as triple-negative breast cancer, where MYT1 activity may contribute to oncogenesis and tumor progression. Myt1-IN-6 serves as a valuable tool for exploring therapeutic strategies targeting MYT1 in various malignancies.
Out of stock
All 3 sizes